MedTech CEO-Only Forum

Dr. David Israeli is the Chairman & CEO of Magenta Medical, a start-up company developing a temporary mechanical circulatory support device for acute indications. Immediately prior to this, David was the Chief Medical Officer of Ossio Ltd., a start-company developing novel implants for orthopedic fixation.

Previously, he was a life sciences General Partner at Pitango Venture Capital, one of the leading VC groups in Israel, where he led investments in the areas of medical devices and digital health.

Before joining Pitango, David was the Director of Business Development and Marketing at Medtronic Ventor Technologies, following Medtronic’s acquisition of Ventor Technologies in 2009.

Prior to this, David spent several years in the United States. After earning an MBA, he joined Medtronic and filled roles ranging from corporate development and M&A to business and market development. David then went on to become the VP of Medical Affairs at Rhythmia Medical, which was acquired by Boston Scientific in 2012.

David holds an MD from the Hebrew University of Jerusalem and an MBA from the Harvard Business School.

Miquel Craven-Bartle Capella is the Chief Executive Officer and Managing Director of Cardionovum GmbH, a German medical device manufacturer headquartered in Bonn, recognized for its breakthrough proprietary coating technology for Drug-Coated Balloons (DCBs) in interventional cardiology and vascular field.

With more than 20 years of experience in MedTech, including over 15 years in leadership roles, Miquel has built his career around bridging innovation and industrial execution to transform breakthrough medical technologies into sustainable business success.

He is recognized for his 360-degree approach to innovation and business transformation, integrating regulatory strategy, clinical validation, market access, manufacturing, commercialization, operational excellence, and organizational development into a single value creation process. Throughout his career, he has successfully introduced disruptive medical technologies into international markets while building high-performing teams and driving sustainable growth.

Since becoming CEO in 2021, Miquel has led Cardionovum’s transformation from an entrepreneurial venture into one of the world’s four leading providers of coronary Drug-Coated Balloon technology by procedure volume. By translating shareholder ambitions into a clear long-term vision, he has expanded the company’s presence to more than 70 countries, scaled manufacturing operations, strengthened profitability, elevated quality standards, and built a robust platform for sustainable growth and long-term shareholder value. Miquel believes lasting success is achieved by combining visionary leadership, empowered people, and operational excellence to transform innovation into global impact.

Ronit Harpaz is Co-Founder and CEO of Endoron Medical, a cardiovascular medical-device company developing technologies across aortic repair and structural heart.

Under her leadership, Endoron has secured FDA IDE approval for a pivotal study of its PMA-pathway Aortoseal technology and attracted backing from leading European investors, including Sofinnova Partners and the European Innovation Council (EIC). Endoron was selected for the highly competitive EIC Accelerator, receiving both grant funding and subsequent equity investment from the EIC Fund.

Ronit spent 15 years in Australia, where she earned a B.App.Sc. (Hons) from the University of Sydney and an MBA from UNSW. Beyond industry, she co-founded the Israeli High-Tech Forum in the Knesset, connecting technology leaders with policymakers. She is also a member of 8400 The Health Network, ICI faculty, Merage alumna, and Co-Founder of WE@HealthTech.

Serial Medtech entrepreneur and inventor, and experienced executive and R&D leader ofmultiple medical device companies in the fields of cardiovascular surgery, hemodialysis, heart failure, neurovascular and pulmonology developing and commercializing first of its kind medical technologies.

Today, serves as co-founder and CEO at Vectorious Medical Technologies which was recently acquired by Edwards Lifesciences, co-founder and chairman at Laminate Medical technologies and founder and chairman at Vascular Graft Solutions.

Hold M.D. from the Bruce Rapaport’ Medical school at the Technion, Israel institute of technology, and MBA from Tel Aviv University. Selected by Goldman Sacks as one of the most intriguing 100 entrepreneurs in the world as part of the Builders and Innovators Summit, 2018.

Eyal Baror is a seasoned CEO with over 25 years of experience in the medical devices sector, specializing in guiding companies through the entire product development life cycle, from early-stage innovation to clinical validation. His proven track record includes managing venture-backed companies to successful exits, notably as CEO of Innovalve Bio Medical, leading it from preliminary stages to its acquisition by Edwards Lifesciences for $350 million, achieving an impressive 10x return for investors in under five years. Eyal’s strategic leadership, alongside his deep scientific knowledge and hands-on management style, has consistently fostered organizational excellence and value creation. He holds advanced degrees in Physics and Mathematics, is a graduate of the prestigious Talpiot program, and is a recognized inventor with dozens of international patents.

Amir Gross is a serial entrepreneur and MedTech executive with a track record of building structural heart companies from concept to successful exit. Across two companies he founded and led as CEO, Amir has generated a combined $1 billion in exits, while advancing technologies designed to transform the treatment of structural heart disease.

Amir is the CEO of Cardiovalve, a developer of transcatheter mitral and tricuspid valve replacement systems. Cardiovalve was acquired by Venus MedTech in 2022 in a $300 million transaction. Following the acquisition, Amir led Venus MedTech’s global heart valve innovation incubator, driving the incubation and development of new therapeutic technologies, including next-generation solutions for aortic regurgitation and the integration of digital health technologies into heart valve systems.

Amir currently serves as Executive Chairman of SmartValves and is co-founder of a stealth-mode startup in the structural heart field, continuing to build and advance new technologies and companies in the space.

Previously, Amir founded and served as CEO of Valtech Cardio, which was acquired by Edwards Lifesciences in a $700 million transaction. At Valtech, he led a team of 70 professionals developing catheter-based technology for repairing a major heart valve without the need for open-heart surgery.

Throughout his career, Amir has combined entrepreneurship, technology development, company building, and leadership in structural heart innovation. His track record includes approximately $200 million in venture capital raised, five structural heart companies in his personal portfolio, and 40 granted patents. In 2017, he received Globes magazine’s Man of the Year Award. Amir is also an angel investor in medical devices, pharmaceuticals, and biotechnology, supporting emerging healthcare technologies and companies.